Purpose: Over the last few years, resistance to ciproß oxacin in Salmonella enterica has become a global concern. The present study was undertaken to Þ nd out the susceptibility pattern of Salmonella enterica isolates in our hospital. Methods: Blood cultures were done using BacT/ALERT 3D system. The antimicrobial susceptibility testing was carried out by the Kirby-Bauer disc diffusion method using CLSI breakpoints. Minimum inhibitory concentration was determined for ciproß oxacin-resistant strains using E-test and Vitek-1 automated system. Results: A total of 25,953 samples of blood culture yielded 431 Salmonella enterica serotype Typhi and 198 serotype Paratyphi A isolates. Twentytwo isolates of serotype Typhi were resistant to ciproß oxacin, while two isolates of Typhi and two Paratyphi A were intermediately susceptible to ciproß oxacin. Ciproß oxacin resistance is 5.6% (24 isolates) among Salmonella enterica serotype Typhi. Ampicillin, chloramphenicol and co-trimoxazole resistance in Salmonella enterica serotype Typhi appears to have decreased to 14.9% (64/431) in comparison to the 27% (55/205) during 2003. All isolates were sensitive to ceftriaxone. Conclusions: Ciproß oxacin can no longer be considered as the drug of choice in treating Salmonella infections. While Þ rst-line antimicrobials may still have a role to play in the treatment of enteric fever, ceftriaxone remains the sole defence against ciproß oxacin-resistant Salmonella infections.
The copies of the journal to members of the association are sent by ordinary post. The editorial board, association or publisher will not be responsible for non-receipt of copies. If any of the members wish to receive the copies by registered post or courier, kindly contact the journal's / publisher's offi ce. If a copy returns due to incomplete, incorrect or changed address of a member on two consecutive occasions, the names of such members will be deleted from the mailing list of the journal. Providing complete, correct and up-to-date address is the responsibility of the members. Copies are sent to subscribers and members directly from the publisher's address; it is illegal to acquire copies from any other source. If a copy is received for personal use as a member of the association/society, one cannot resale or giveaway the copy for commercial or library use. Enteric fever is a major public health problem in the developing world. It affects 6 million people worldwide with more than 600,000 deaths a year. Almost 80% of the cases and deaths are in Asia and the rest occur mostly in Africa and Latin America. [1] Enteric fever is endemic in many developing countries, including India and, if not treated appropriately, has a mortality rate of 30%. Appropriate treatment reduces the mortality rate to as low as 0.5%. [2] Chloramphenicol was introduced in 1948 as the Þ rst effective antibiotic in the treatment of typhoid fever. Even though resistance started to develop within two years of its introduction, it did not emerge as a major problem until 1972. [3] Chloramphenicol resistance was associated with high molecular weight, self-transferable, Inc HI plasmids. Amoxicillin and co-trimoxazole were the effective alternatives till the development of 'multidrug resistant (MDR) strains' (resistant to ampicillin, chloramphenicol and co-trimoxazole -ACCo) towards the end of 1980s and 1990s. [3] These MDR strains also carry the Inc HI plasmids that encoded the resistant genes. MDR Salmonella enterica serotype Typhi are still common in many areas, although in some regions fully sensitive strains have re-emerged.
Ciprofl oxacin Breakpoints in Enteric Fever -Time to Revise our Susceptibility Criteria
The emergence of MDR Salmonella enterica isolates led to the use of ß uoroquinolones (ciproß oxacin and oß oxacin) as the Þ rst-line drugs for its treatment. Fluoroquinolones have good in vitro and clinical activity against salmonellae and became the treatment of choice in cases of MDR salmonellosis. [4] Isolates with low-level resistance (MIC ≥0.25 µg/mL but <4 µg/mL) to ß uoroquinolones appeared within a few years of this change. [5] [6] [7] [8] Quinolone resistance is frequently mediated by single-point mutations in the quinolone resistance determining region of the gyr A gene, characteristically occurring at position 83 of the DNA gyrase enzyme (changing serine to phenylalanine) and position 87 (changing aspartate to tyrosine or glycine). [7] Until recently, quinolone resistance was believed to arise solely from chromosomal mutations in genes encoding target enzymes or due to decreased accumulation of the drug inside the bacteria. In 1998, mobile elements with the potential for horizontal transfer of quinolone resistance genes were described. [9] The locus responsible for this plasmidmediated quinolone resistance, designated qnr A, qnr B and qnr S, has been identiÞ ed in Enterobacteriaceae species. [10] The qnr A gene confers nalidixic acid (NA) and low-level ß uoroquinolone resistance and its presence has been shown to facilitate selection of chromosomal mutations that confer higher levels of resistance. [9] This plasmid-mediated quinolone resistance was unknown in Salmonella enterica until recently. There is a report of plasmid-mediated quinolone resistance in non-Typhi serotypes of Salmonella enterica carrying either qnr B or qnr S from United States. [11] Plasmid-mediated quinolone resistance in Salmonella is of great concern, since horizontal transfer of quinolone resistance would facilitate rapid dissemination of the quinolone resistance genes, further compromising the use of these antimicrobial agents.
Given the variation in the susceptibility patterns reported for Salmonella enterica, it is important to constantly monitor its susceptibility so as to provide suitable guidelines for treatment. The present study was undertaken to Þ nd out the susceptibility pattern of Salmonella enterica isolates in a tertiary health care facility in Delhi, India.
Materials and Methods
A total of 25,953 blood culture samples collected in BacT/ALERT 3D culture bottles (bioMéuriex, France) were processed in the Department of Clinical Microbiology, Sir Ganga Ram Hospital, New Delhi over a period of 20 months (1 January 2005-31 August 2006). Positive blood cultures (signalled by the BacT/ALERT 3D machine) were processed; and the isolates were identiÞ ed as Salmonella enterica serotype Typhi and Paratyphi A by standard biochemical methods [12] and conÞ rmed by slide agglutination with speciÞ c antisera (Salmonella agglutinating serum, Remel, Europe) The antimicrobial susceptibility testing was carried out by the Kirby-Bauer disc diffusion method [13] using CLSI breakpoints. The antimicrobial agents tested were ampicillin (10 µg), chloramphenicol (30 µg), co-trimoxazole (25 µg), NA (30 µg), ceftriaxone (30 µg), ciproß oxacin (5 µg) and ceÞ xime (5 µg) (Hi-Media Laboratories, Mumbai). Minimum inhibitory concentration (MIC) was determined for the ciproß oxacin-resistant strains by E-test (AB Biodisk, Sweden) and Vitek-1 automated system (bioMéuriex, France), as per the manufacturers' speciÞ cations. Table 1 . Among the NAresistant strains, 22 isolates of serotype Typhi were showing high-level resistance, two isolates of serotype Typhi and two isolates of serotype Paratyphi A were intermediate susceptible to ciproß oxacin (deÞ ned as MIC >1 µg/mL but <4 µg/mL) and the rest were sensitive. All NA-sensitive strains of serotype Typhi as well as Paratyphi A were sensitive to ciproß oxacin (MIC <0.25 µg/mL).
Results

Of the
25,953 blood culture samples, a total of 632 strains of Salmonella enterica were isolated. Of these, 431 were Salmonella enterica serotype Typhi, 198 were Salmonella enterica serotype Paratyphi A, two were Salmonella enterica serotype Enteritidis and one was Salmonella enterica serotype Typhimurium. The pattern of antimicrobial resistance of the 431 Salmonella enterica serotype Typhi and 198 serotype Paratyphi A isolates is shown in
Antibiogram of Salmonella enterica serotype Typhi and
Paratyphi A is shown in Table 2 . All isolates were sensitive to ceftriaxone. Sensitivity testing for ceÞ xime was started recently and all 45 isolates of serotype Typhi and 13 isolates of serotype Paratyphi A tested were found to be sensitive.
The Fig. 1 shows the distribution of MIC of ciproß oxacin among serotype Typhi and Paratyphi A isolates that were resistant to ciproß oxacin. Twenty (83.3%) of the 24 Typhi isolates had an MIC of ≥24 µg/mL while both isolates of Paratyphi A had an MIC of 1.5 µg/mL. All the ciproß oxacinresistant isolates were sensitive to ampicillin, chloramphenicol and ceftriaxone but 13 serotype Typhi isolates were resistant to co-trimoxazole.
Discussion
The resistance pattern of Salmonella enterica had been varying with time and geographical locations. In our hospital, since April 2003, after noticing inadequate response to treatment with quinolones, NA susceptibility testing was started routinely for all Salmonella isolates. NA-resistant Salmonella isolates were found to have almost tenfold higher MIC to ciproß oxacin. [8] The Þ rst high-level ciproß oxacinresistant (deÞ ned as MIC ≥4 µg/mL) strain was isolated in our hospital in July 2005 with an MIC of >32 µg/mL. Following that, 21 more high-level ciproß oxacin-resistant and two intermediately susceptible Salmonella enterica serotype Typhi strains and two intermediately susceptible strains of serotype Paratyphi A were isolated. Highlevel ciproß oxacin resistance increased to 6.78% in 2006 (16 Salmonella enterica serotype Typhi and no Paratyphi A) from 1.52% (6 Salmonella enterica serotype Typhi and no Paratyphi A) in 2005. This increase in high-level ciproß oxacin resistance probably reß ects the overuse or irrational use of ciproß oxacin in the treatment of typhoid as well as in other unrelated infections. Incomplete treatment may be another factor contributing to development of resistance.
There are several reports of therapeutic failure of ß uoroquinolones in patients with enteric fever. [14, 15] Although reported as susceptible by disc diffusion assay using recommended breakpoints to ß uoroquinolones, these isolates have smaller zones of inhibition to ß uoroquinolones by KirbyBauer disc diffusion method and MIC is almost tenfold higher than fully susceptible strains. [6, 8] In recent years, there are some sporadic reports of high-level ciproß oxacin resistance in Salmonella enterica. [5, 16] Renuka et al. reported isolation of Salmonella enterica serotype Typhi strains showing highlevel resistance to ciproß oxacin. [17] The exact mechanism of ß uoroquinolone resistance in Salmonella enterica serotype Typhi and Salmonella enterica serotype Paratyphi A is not fully understood. Various studies have found that a single mutation in the gyr A gene is sufÞ cient to confer resistance to NA and reduced susceptibility to ß uoroquinolones, and a second mutation leads to high-level ß uoroquinolone resistance. [17] In view of the above case reports of therapeutic failure of ciproß oxacin in NA-resistant cases (NA resistance was >90% in the present study) and the recent emergence of high-level ciproß oxacin resistance, ciproß oxacin can not be considered the Þ rst choice of antimicrobial for empiric treatment of enteric fever.
All the isolates in our study were sensitive to ceftriaxone in contrast to some studies that recorded resistance to ceftriaxone. [18, 19] Therefore, ceftriaxone is advised to be a reserve drug for treating MDR and ciproß oxacin-resistant cases.
An interesting observation in our study is that multidrug resistance in Salmonella enterica serotype Typhi has come down to 14.9% in comparison to the 27% during 2003 (55/205). [8, 20] Moreover, ACCo resistance was not observed in serotype Paratyphi A. One recent study published from North India also shows the same observation; [21] this trend encourages the use of Þ rst-line antibiotics in sensitive cases.
The current study suggests that ciproß oxacin can no longer be considered the drug of choice in treating Salmonella infections due to its high-level resistance. The resistance to Þ rst-line antimicrobials (ACCo) appears to be waning in serotype Typhi and not yet appeared in serotype Paratyphi A. Based on our experience of in vitro susceptibility pattern, ACCo may be considered in the empiric therapy of enteric fever. If susceptibility shows otherwise, the therapy can be switched to ceftriaxone. No ceftriaxone resistance was observed in our study. While Þ rst-line antimicrobials may still have a role to play in the treatment of enteric fever, ceftriaxone remains the sole defence against ciproß oxacinresistant Salmonella enterica serotype Typhi and Paratyphi A. The usage of this drug in the empiric therapy should be discouraged. Considering the rapid emergence of highlevel ciproß oxacin resistance, is it time to re-think about ciproß oxacin breakpoints or an alternate therapy for enteric fever?
